Form 4: LifeStance Director Sells Shares Under 10b5-1 Plan

LifeStance Health Group Director Robert Bessler reported sales of common stock totaling 121,643 shares across multiple entities under a pre-arranged 10b5-1 plan.

Summary

• Robert Bessler, a Director of LifeStance Health Group, Inc. (LFST), reported sales of common stock.
• The transactions were executed under a Rule 10b5-1(c) pre-arranged trading plan.
• On December 19, 2025, Vitthal LLC and Shama LLC each sold 59,971 shares of common stock at a weighted average price of $7.04 per share.
• On December 22, 2025, Vitthal LLC sold 850 shares and Shama LLC sold 851 shares of common stock, both at a weighted average price of $7.04 per share.
• Following these transactions, Vitthal LLC beneficially owns 1,318,133 shares, and Shama LLC beneficially owns 1,434,932 shares.
• Robert Bessler also directly holds 57,619 shares and indirectly holds 36,363 shares through Alpine Glow Capital, where he is the manager and sole member.
• The reported prices are weighted averages, with individual transaction prices ranging from $7.00 to $7.065 on December 19, 2025, and $7.03 to $7.04 on December 22, 2025.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a director selling shares, which can sometimes be perceived as a lack of confidence. However, the fact that it's under a 10b5-1 plan mitigates some of the negative implications, suggesting a pre-planned liquidity event rather than a reaction to adverse news.

Positives

• The sales were conducted under a Rule 10b5-1 plan, indicating they were pre-scheduled and not necessarily a reaction to recent non-public information.

Negatives

• A director selling a significant number of shares, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces insider ownership.

Risks

• No explicit risks are mentioned in this Form 4 filing. The act of selling shares by an insider, even under a 10b5-1 plan, could be interpreted by some investors as a signal of reduced confidence, though this is not a direct risk stated in the document.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity and does not provide specific insights into broader industry trends or competitive landscape for the healthcare services sector. Insider selling, even under a 10b5-1 plan, is a common occurrence and its interpretation often depends on the overall market conditions and company-specific news.

Related Party Transactions

• Sales were conducted by Vitthal LLC and Shama LLC, entities associated with the reporting person, Robert Bessler.
• Robert Bessler is the manager and sole member of Alpine Glow Capital, which also holds shares indirectly.

Stakeholder Impact

• Shareholders: The sale of shares by a director could potentially lead to a slight negative sentiment or increased selling pressure on the stock, although the 10b5-1 plan mitigates this.

Key Dates

Recommendation

While a director selling shares can sometimes be a negative signal, the transactions were executed under a pre-arranged 10b5-1 plan, suggesting a planned liquidity event rather than a reaction to new adverse information. Without additional context on the company's performance or strategic direction, this Form 4 alone does not warrant a change from a 'hold' position, as it's a routine insider disclosure.

Keywords

LifeStance Health Group, LFST, Robert Bessler, Insider Trading, Form 4, Stock Sale, Director, 10b5-1 Plan, Beneficial Ownership